BRODIE et al, 1995:
Duration: 9 months;
Trial size: CBZ 129, LTG 131;
Average Dose: CBZ 600mg/day, LTG 150mg/day;
Withdrawal rate: CBZ 49%, LTG 35%;
Side-effect rate: CBZ 74%, LTG 56%;
REUNANEN et al, 1996:
Duration: 30 months;
Trial size: CBZ 117, LTG 111;
Average Dose: CBZ 600mg/day, LTG 100 or 200mg/day;
Withdrawal rate: CBZ 24.8%, LTG 9% (200mg/day);
Side-effect rate: CBZ 66%, LTG 58% (200mg/day);
STEINER & YUEN, 1994:
Duration: 10 months;
Trial size: LTG 86, PHT 95;
Average Dose: LTG 150mg/day, PHT 300mg/day;
Withdrawal rate: LTG 15%, PHT 19%;
Side-effect rate: neither stated in published trial;
RICHENS et al, 1994:
Duration: 6 and 36 months;
Trial size: CBZ 151, VPA 149;
Average Dose: CBZ 516mg/day, VPA 924MG/DAY;
Withdrawal rate: CBZ 36% (36 months), VPA 26% (36 months);
Side-effect rate: CBZ 48.9% (36 months), VPA 49.4% (36 months);
HELLER et al, 1995:
Duration: 30 months;
Trial size: CBZ 61, PHT 63, VPA 61;
Average Dose: all not stated in published trial;
Withdrawal rate: CBZ 11%, PHT 3%(i), VPA 5%(i);
Side-effect rate: all not stated in published trial;
CALLAGHAN et al, 1985:
Duration: 14-18 months (ii);
Trial size: CBZ 59, PHT 58, VPA 64;
Average Dose: CBZ 10.9mg/day, PHT 5.4mg/kg/day, VPA 15.6mg/kg/day;
Withdrawal rate: CBZ 14%, PHT 9%, VPA 14%;
Side-effect rate: CBZ 8.5%, PHT 10.3%, VPA 10.9%;
RAMSEY et al, 1983:
Duration: 24 months;
Trial size: CBZ 35, PHT 35;
Average Dose: CBZ 9.3mg/kg/day (iii), PHT 5.4mg/kg/day;
Withdrawal rate: CBZ 23%, PHT 23%;
Side-effect rate: CBZ 'Half', PHT 'Half';
TURNBULL et al, 1985:
Duration: 24 months;
Trial size: PHT 45, VPA 45;
Average Dose: neither stated in published trial;
Withdrawal rate: PHT 29%, VPA 26%;
Side-effect rate: neither stated in published trial;
(i) = Percentage of patients withdrawn due to adverse events. The total percentage of patients withdrawn was not stated.
(ii) = Median follow-up varied between CBZ partial seizures 14 months, generalised 15 months; PHT partial seizures 18 months, generalised 24 months; and VPA partial seizures 24 months, generalised 24 months.
(iii) = Mean dose stated for the group of patients 'who suffered no major side-effects and in whom efficacy of a single medication could be evaluated'.